Hanmi Pharm's cefixime won COS

Published: 2003-09-22 06:58:00

Updated: 2003-09-22 06:58:00

Hanmi Pharm said that it has acquired from the European Pharmacopoeia Commission the certification of suitability (COS) on cefixime, antibiotic bulk material, for the third time following ceftriaxone and cefotaxime, adding that its COS acquisitions reflect the largest number among domestic pharmaceutical firms.

The COS has been recognized as the most authoritative certification procedure in ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.